Ethos Discovery and Gallant Therapeutics Collaborate on Study Evaluating Gallant’s Stem Cell Therapy in Pugs with Necrotizing Meningoencephalitis (NME), also referred to as Pug Dog Encephalitis (PDE)
October 03, 2023 08:12 ET
|
Gallant Therapeutics
Gallant Therapeutics and Ethos Discovery collaborate in a clinical study evaluating the use of stem cells to treat pugs with early-stage NME
Albumin Market revenue to cross USD 10 Billion by 2035, says Research Nester
October 02, 2023 06:30 ET
|
Research Nester
New York, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The global albumin market size is slated to expand at ~ 6% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 10 Billion by the...
Interim results for the six months ended 30 June 2023
September 29, 2023 16:30 ET
|
Biodexa Pharmaceuticals PLC
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage...
Tonix Pharmaceuticals Announces Pricing of $4.5 Million Public Offering
September 28, 2023 21:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced it has entered into...
Tonix Pharmaceuticals Announces Proposed Public Offering
September 28, 2023 16:01 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced that it intends to offer...
Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina’s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Disorder
September 27, 2023 08:30 ET
|
Tonix Pharmaceuticals Holding Corp.
$3 million awarded by DoD to University of North Carolina Institute of Trauma Recovery to support a proposed 180-patient, randomized, placebo-controlled trial in acute trauma patients Investigator...
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
September 21, 2023 08:30 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at...
Tonix Pharmaceuticals Presents New Preclinical Data at Seventh International Cancer Immunotherapy Conference 2023
September 21, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
mTNX-1700 (mTFF2-MSA) suppresses tumor growth and increases survival rates in preclinical colorectal cancer models mTNX-1700 shows single agent activity and additive effects in combination with...
Tonix Pharmaceuticals Announces Presentation of Non-Clinical Studies Supporting the Mechanism of TNX-1900 (Intranasal Potentiated Oxytocin) at the 2023 International Headache Congress
September 18, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Oxytocin receptors and CGRP are co-expressed on human trigeminal ganglia neurons and their expression is increased in inflammation Human tissue data support the proposed mechanism of action of...
Peer-Reviewed Publication of Positive Preclinical Data of SiSaf’s SIS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis
September 18, 2023 04:00 ET
|
SiSaf Ltd
GUILDFORD, United Kingdom, Sept. 18, 2023 (GLOBE NEWSWIRE) -- SiSaf Ltd, an RNA therapeutics company, is pleased to announce the publication in the peer-reviewed journal Molecular Therapy Nucleic...